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Abstract 
BACKGROUND: Combined modality therapy is standard of care for patients with inoperable locally advanced 
non-small cell lung cancer (NSCLC), however, insufficient data exist regarding what chemoradiotherapy 
combination will be the gold standard. 
AIM: The study aimed to compare the survival impact and side effects of concurrent versus sequential 
radiochemotherapy treatment in inoperable stage III non-small cell lung cancer (NSCLC).  
METHODS: To evaluate the treatment results and prognostic variables, 85 NSCLC patients treated from October 
2005 to November 2008 were randomly assigned to one of the two treatment arms. In the first arm (sequential 
arm), 45 patients received sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by 
conformal 3-dimensional (3D) radiotherapy (RT). In the second arm (concurrent arm), 40 patients received 
concomitant chemotherapy with cisplatin and etoposide and conformal RT, followed by two cycles of consolidation 
chemotherapy with carboplatin and etoposide 
RESULTS: The median survival was 13 months for the patients in the sequential arm and 19 months for those in 
the concurrent treatment arm (p = 0.0039). The disease-free survival (DFS) was 9 months in the sequential arm 
and 16 months in the concurrent treatment arm (p = 0.0023). Seven complete responses and 18 partial responses 
were obtained with sequential treatment. Twelve complete responses and 21 partial responses were obtained in 
concurrent arm. The differenced were statistically significant p = 0.03. Median survival for patients with complete 
response in concurrent treatment arm was 36 months versus 18 mounts for a sequential arm; partial response 
was 27 months versus 16 months and those with stable disease 11 months versus 9 months. Treatment-related 
toxicities were assessed according to the RTOG/EORTC criteria. Acute esophagitis and incidence of neutropenia 
were higher with the concurrent than with sequential treatment. Grade 3 esophagitis was characteristic only for 
concurrent treatment, and it was the reason for radiotherapy interruption, but no longer than 7 days. Secondary 
anaemia was more frequent in the sequential treatment arm. 
CONCLUSION: The statistically significant differences in survival were suggested that the concurrent 
chemotherapy and conformal three-dimensional radiotherapy is the optimal strategy for patients with locally 
advanced NSCLC with acceptable toxicity rates. 
 
 
 
 
 
 
Introduction 
 
Lung cancer remains a worldwide epidemic. 
Approximately 1.2 million people die from lung cancer 
each year. NSCLC patients represent more than 80% 
of all lung cancers. Of the patients with NSCLC, 60-
70% present with Stage III or IV disease. In the late 
1980s, radiotherapy was the standard treatment for 
these patients [1]. Randomised trials and a 1995 
overview subsequently showed that combination 
chemoradiotherapy was superior to radiotherapy 
alone [2]. Many chemotherapeutic agents active in 
NSCLC possess radiosensitising properties, thereby 
improving the probability of local control. Also, 
chemotherapy administered concurrently with thoracic 
radiation may act systemically and potentially 
eradicate distant micro-metastases. Several studies 
showed the feasibility of the cisplatin-etoposide 
combination plus radiotherapy for patients with stage 
III disease [3]. The primary endpoint on this study was 
the effect of sequential and concurrent 
chemoradiotherapy on overall survival. 
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Material and Methods 
 
This study was prospective, randomised and 
started in the Institute of Radiotherapy and Oncology 
in Skopje, October 2005. Eligible 85 patients were 
aged between 18 and 70 years, had an Eastern 
Cooperative Oncology Group (ECOG) Score ≤ 1 and 
had ≤ 10 % weight loss in 3 months before inclusion. 
They have previously untreated histological or 
cytological proven NSCLC, unrespectable stage IIIA-
N2 disease, or stage IIIB disease without pleural 
effusion. Stage IIIB disease was assigned either by 
N3 (contralateral mediastinal or supraclavicular 
nodes) or by T4 from the invasion of mediastinal 
structures. The following laboratory values were 
required: leucocytes ≥ 1.5 x 10³/l, platelets ≥ 100 x 
10/l, AST and ALT ≤ 2 x the upper limit of the referent 
rang. Ineligibility criteria were as follows: uncontrolled 
infection, or fever over 38ºC, unstable cardiovascular 
disease and previous malignancy. 
Before enrollment, the patients gave their full 
medical histories and underwent a clinical 
examination with assessment of performance status 
(PS). Patients were randomly assigned to receive 
sequential or concurrent therapy. Patients were 
randomly assigned to receive sequential or concurrent 
therapy. In the sequential arm, 45 patients received 
four cycles of chemotherapy. They were administered 
first, consisting of carboplatin (AUC x 6) on day 1 and 
etoposide on days 1-3, repeated every 3 weeks. The 
radiotherapy began 4 weeks after the fourth cycle of 
chemotherapy administration. Chemotherapy and 
radiotherapy began simultaneously in concurrent arm 
consisted of 40 patients. The first cycle of 
chemotherapy, with cisplatin 30 mg/m² and etoposide 
100 mg/m² was administered on days 1 to 3, and the 
second cycle of chemotherapy was administered the 
last 3 days of conformal radiotherapy, in concurrent 
arm. After 4 weeks of concurrent chemoradiotherapy 
schedule, two cycles of consolidation chemotherapy 
began, consisting of carboplatin (AUC x 6) and 
etoposide 100 mg/m² on day 1 to 3. 
Conformal radiotherapy at both arms 
consisted of 60 Gy in 30 fractions of 2 Gy per fraction, 
for 5 days a week given throughout 6 weeks. A 
treatment planning CT was required to define the 
gross tumour volume (GTV). Each patient was 
positioned in an immobilisation device-wing board in 
the treatment position on a flat table. CT slices with 5 
mm thickness were obtained starting from cricoid 
cartilage and extending inferiorly to the level of the L1 
vertebral body. The GTV, clinical target volume (CTV), 
planning target volume (PTV) and normal organs were 
outlined on all CT slices. The normal tissues 
contoured included lungs (as the total lung volume), 
heart, spinal cord and oesophagus. The CTV included 
the entire GTV plus 0.7 cm, and the PTV included 
CTV plus another 0.7 cm adding margin. PTV44 was 
treated with parallel-opposed anterior-posterior fields 
and PTV60 was treated with any combination of fields 
depends on spinal cord constrain. If radiotherapy had 
to be delayed for more than 7 days, the patient was 
withdrawn from the study.  
In the sequential arm, responses were 
assessed 8 weeks after the end of radiotherapy. In the 
concurrent arm, responses were assessed 8 weeks 
after the end of the consolidation chemotherapy. 
Imaging studies x-ray and/or computed tomography 
(CT) could be repeated at all times when clinically 
indicated. Complete and partial responses were 
based on RECIST criteria. Toxicity was graded 
according to RTOG/EORTC criteria. Follow-up visits 
were conducted every 2 months during the first year 
and after that every 3 months. Patients with evidence 
of progression at any time were removed from the 
study but continued to be evaluated for survival and 
toxicity. Survival and the interval to recurrence or 
progression were measured from the date of the first 
treatment session.  
 
 
Results 
 
One hundred and ten patients were identified 
from our database. Of these, 25 were excluded from 
analysis: 7 had metastatic disease, 7 had sudden 
deterioration of their general condition, 3 patients had 
pleural effusion, loss of data or loss of any contact in 3 
patients, and 5 patients due to delivered tumour dose 
less than 60 Gy. Eighty-five patients were 
subsequently included for further analyses. The 
characteristics of 85 patients are listed in Table 1. 
Table 1: Patient and disease characteristics 
 
 
Characteristics 
 
 
Concurrent chemoradiotherapy 
arm 
(N = 40) 
N (%) 
 
Sequential 
chemoradiotherapy arm 
(N = 45) 
N (%) 
 
p-value 
Age, years 
18-43 
44-55 
56-70 
 
0 
20 (50) 
20 (50) 
 
1 (2) 
13 (29) 
32 (71) 
0.13 
Sex 
Male 
 Female 
 
35 (88) 
5 (12) 
 
40 (89) 
5 (11) 
0.98 
Performance status 
0 
1 
 
26 (65) 
14 (35) 
 
23 (51) 
22 (49) 
0.19 
Weight loss (%) 
< 5 
5-10 
 
26 (65) 
14 (35) 
 
23 (51) 
22 (49) 
0.13 
Histology 
 Squamous cell 
 Adenocarcinoma 
 Large cell 
 Unspecified 
 
22 (55) 
10 (25) 
3 (7) 
5 (1) 
 
34 (75) 
6 (13) 
2 (4) 
3 (6) 
0.26 
N status 
 N1 
 N2 
 N3 
 
 
12 (30) 
25 (63) 
3 (7) 
 
15 (33) 
27 (60) 
3 (7) 
0.93 
T status (cm) 
Tumor ≤ 5  
Tumor > 5  
 
13 (32) 
27 (68) 
 
21 (47) 
24 (53) 
0.38 
Hemoglobin (g/dl) 
<12 
≥12 
 
11 (27) 
29 (73) 
 
19 (42) 
26 (58) 
0.15 
Duration of symptoms 
(months) 
< 3  
3-6  
> 6  
 
2 (5) 
21 (53) 
17 (43) 
 
0 
23 (51) 
22 (49) 
0.29 
 
Survival was analysed until March 2010. The 
median OS was 13 months in the sequential arm 
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(95% CI 10.2-15.7), and 19 months in the concurrent 
treatment arm (95% CI 13.6-24.3), with statistically 
significant difference (log-rank test, p = 0.0039; Figure 
1).  
 
Figure 1: Overall survival according to the treatment arm (p = 
0.0039) 
 
The 1, 2 and 3-year OS rates were 74, 36 and 
27% in the concurrent arm and 52, 14 and 7.1% in the 
sequential arm (p = 0.0039). DFS for the concurrent 
arm was 16 months (95% CI 12.7-19.2), and for the 
sequential arm, it was 9 months (95% CI 5.8-12.16). 
The difference was statistically significant (log-rank 
test, p = 0.0023; Figure 2).  
 
Figure 2: Disease-free survival according to the treatment arm (p = 
0.0023) 
 
Survival time was insignificant correlation with 
local tumor control (p < 0,001). Local tumour response 
was evaluated for each patient included in the study 
(Table 2). Seven patients with complete response and 
18 with partial responses were obtained treated with 
sequential treatment. Twelve patients with complete 
response and 21 with partial response were obtained 
in the concurrent treatment arm. According to tumour 
responses, the difference between treatment arms 
was statistically significant p = 0.03. Median survival 
for patients with complete response in concurrent 
treatment arm was 36 months versus 18 months in 
sequential arm. Median survival for patients with 
partial response in the concurrent arm was 27 months 
versus 16 mounts in sequential arm and for those 
patients with stable disease median survival was 11 
months in concurrent arm versus 9 months in the 
sequential treatment arm. 
Table 2: Tumor response in concurrent and sequential 
treatment arm 
Treatment 
arm 
CR 
Complete 
response 
PR 
Partial 
response 
CR + PR 
Objective 
response 
SD 
Stabile 
disease 
NR No 
response 
Patients 
Concurrent 
arm 
12 (30%) 21 (53%) 33 (83%) 3 (7%) 4 (10%) 40 
Sequentional 
arm 
7 (16%) 18 (40%) 25 (56%) 12 (27%) 8 (18%) 45 
 19 (22%) 39 (46%) 58 (68%) 15 (18%) 12 (14%) 85 (100%) 
p = 0.04573; SS = 3; x² = 8.01350. 
 
 Prognostic factors with a significant influence 
on survival were: initial performance status according 
to ECOG, initial weight loss, nodal involvement, 
tumour size and ages. Prognostic factors without any 
influence on survival were: gender, duration of 
symptoms, haemoglobin level and histological type. 
Table 3: Treatment toxicity according to RTOG/EORTG criteria 
in sequential arm and concurrent arm 
Treatment toxicity  
Sequential arm 
 
Concurrent arm 
Grade 
0 
Grade 
1 
Grade 
2 
Grade 
3 
Grade 
0 
Grade 
1 
Grade 
2 
Grade 
3 
Early Lungs 
9 
(20%) 
24 
(53%) 
10 
(22%) 
2 
(4%) 
3 
(8%) 
24 
(60%) 
8 
(20%) 
5 
(13%) 
 Esophagus 
17 
(38%) 
20 
(44%) 
8 
(18%) 
0 
2 
(5%) 
20 
(50%) 
15 
(37%) 
0 
 
 Hemoglobin 
24 
(53%) 
14 
(31%) 
7 
(15%) 
0 
35 
(88%) 
4 
(10%) 
1 
(2%) 
0 
 Leucocytes 
41 
(91%) 
2 
(4.4%) 
2 
(4.4%) 
0 
13 
(32%) 
11 
(27%) 
14 
(35%) 
2 
(5%) 
Late Lungs 
7 
(16%) 
23 
(51%) 
9 
(20%) 
0 
 
8 
(20%) 
16 
(40%) 
11 
(27%) 
5 
(12%) 
 
Esophagus 
36 
(80%) 
5 
(11%) 
4 
(8%) 
0 
30 
(75%) 
3 
(7%) 
7 
(17%) 
0 
 
 
Treatment-related toxicities according to 
RTOG/EORTC are listed in Table 3. Acute 
esophagitis and incidence of neutropenia were higher 
with the concurrent than with sequential treatment 
arm. Grade 3 esophagitis was characteristic only for 
concurrent treatment, and it was the reason for 
radiotherapy interruption but no longer than 7 days. 
Secondary anaemia was frequent in the sequential 
treatment arm. Due to these results, adverse effects 
of both chemoradiotherapy arms were mild and 
moderate. 
 
 
Discussion 
 
Randomised phase III trial comparing 
sequential and concurrent administration of 
chemotherapy and radiation therapy for NSCLC has 
been published so far [4]. In the study of Furuse et al., 
the West Japan Group, chemotherapy combined 
cisplatin, vindesine and mitomycin C. The total dose 
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of radiotherapy was 56 Gy, and in the concurrent arm, 
was administered in a split-course schedule, with a 
rest period of 10 days. Median survival was 
significantly better with concurrent therapy than with 
sequential therapy (16.5 and 13.3 months, 
respectively; p = 0.0398). The 2-, 3-, and 5-year 
survival rates were, respectively, 34.6%, 22.3% and 
15.8% in concurrent arm, and 27.4%, 14.7% and 
8.9% in the sequential arm. Radiation Therapy 
Oncology Group (RTOG) study 94-10 [5] compares 
sequential treatment with concurrent therapy in which 
the same dose of radiotherapy 63 Gy was 
administered during the two cycles of cisplatin-
vinblastine therapy, and with concurrent treatment 
using a bi-fractionated and accelerated irradiation 
69.6 Gy combined with two cycles of cisplatin-
etoposide. The median survival rate in the concurrent 
treatment with cisplatin-vinblastine and standard 
radiotherapy was significantly better than that in the 
sequential arm (17 v 14.6 months; p = 0.046). The 
median survival rate in bi-fractionated irradiation was 
15.2 months. The third study which supports the 
concomitant approach was from Zatloukal PV, 2004. 
Chemotherapy in both groups consisted of 4 cycles of 
cisplatin and vinorelbine every 4 weeks. Radiotherapy 
of 60 Gy was started in concurrent arm with the 
second cycle and in sequential arm 2 weeks after 
completion of the chemotherapy. Median survival time 
in the concurrent group was 16.8 months and in the 
sequential group was 12.9 months (p = 0.0216, log-
rank test). Median time to progression was 11.9 in 
concurrent arm and 8.5 in sequential arm, respectively 
[6]. 
Our study compared sequential and 
concurrent chemoradiation therapy in locally 
advanced NSCLC. We found a benefit of concurrent 
therapy more than in previously listed trials, regarding 
overall and disease-free survival (19 vs 13; 16 vs 9 
months), and the difference was significant with the 
log-rank test. When our study was designed, the 
cisplatin-etoposide combination was mostly used 
concurrently with radiotherapy [7]. Consolidation 
chemotherapy with two cycles of carboplatin-
etoposide was administered in the concurrent arm to 
balance the dose of platinum-based chemotherapy in 
the two arms. This consolidation chemotherapy 
administered after concurrent chemoradiotherapy 
seems promising regarding survival, as shown in the 
Southwest Oncology Group (SWOG) S9504 and 
Locally Advanced Multimodality Protocol (LAMP) 
studies [8], [9]. In the SWOG S9504 study, 
consolidation docetaxel following concurrent 
chemoradiotherapy, shown a median survival of 26 
months and median progression-free survival of 16 
months. Our concurrent-consolidation arm was shown 
similar results (OS 19 months and DFS 16 months). In 
our study, the local relapse rate was lower in the 
concurrent arm than in the sequential arm. In the 
RTOG 94-10 [5] study, local failure rates at 2 years 
were significantly lower in the concurrent arm. Thus it 
seems that the superior survival observed with 
concurrent treatment is associated with better local 
control.  
We didn’t observe major toxicity in our study. 
The incidence of grade 3 esophagitis was lower than 
in RTOG 94-10 study and the possibility for incidence 
reduction in our study was performing conformal 3D 
RT. The same findings were shown by Socinski et al., 
[10], [11]. The North Central Cancer Treatment Group 
(NCCTG) reported a phase I trial escalating the dose 
of RT with 3-D planning between 70 and 78 Gy [12], 
[13]. They defined maximum-tolerated dose as 74 Gy 
and reported an impressive median survival time of 37 
months. The dose-limiting toxicities were mainly 
pulmonary. These results suggest that the dose and 
technical aspects of RT delivery are important in the 
combined modality approach for stage III NSCLC. 
In conclusion, the statistically significant 
differences in survival were suggested that the 
concurrent chemotherapy and conformal three-
dimensional radiotherapy is the optimal strategy for 
patients with locally advanced NSCLC with acceptable 
toxicity rates. To date, it seems that more favourable 
outcomes may require than two cycles of full-dose 
systemic therapy, as well as chemotherapy concurrent 
with radiotherapy. In our study the dose-limiting 
toxicity, esophagitis was reduced by performing 
conformal radiotherapy 
 Conformal thoracic radiotherapy allows dose 
escalating and can probably improve survival and 
local control.   
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